Isotechnika Pharma receives Canadian National Research Council funding for NICAM

Canadian biotech Isotechnika Pharma has received funding from the Canadian National Research Council’s Industrial Research Assistance Program for its Non- immunosuppressive Cyclosporin Analog Molecules (NICAM). Said Dr. Launa Aspeslet, COO of Isotechnika, “This funding is an external validation of our NICAM program awarded through a peer-reviewed process. Research shows that cyclophilin inhibitors have neuroprotective effects which open broad therapeutic areas of completely unmet medical need to Isotechnika such as stroke, Alzheimer’s, Parkinson’s and Lou Gehrig’s disease.” Isotechnika will use the funding to identify and develop lead candidates for neuroprotection.

Click here to read more.

Share this: